Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:VLON

Vallon Pharmaceuticals (VLON) Stock Price, News & Analysis

Vallon Pharmaceuticals logo

About Vallon Pharmaceuticals Stock (NASDAQ:VLON)

Key Stats

Today's Range
$0.62
$0.71
50-Day Range
$0.27
$2.87
52-Week Range
$0.21
$12.92
Volume
279,280 shs
Average Volume
5.78 million shs
Market Capitalization
$8.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

Receive VLON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vallon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VLON Stock News Headlines

Questcor Pharmaceuticals,
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
See More Headlines

VLON Stock Analysis - Frequently Asked Questions

Shares of Vallon Pharmaceuticals reverse split on the morning of Monday, April 24th 2023. The 1-30 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Vallon Pharmaceuticals (VLON) raised $15 million in an IPO on Wednesday, February 10th 2021. The company issued 1,700,000 shares at $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vallon Pharmaceuticals investors own include Meta Platforms (META), Alkaline Water (WTER), SoFi Technologies (SOFI), Exro Technologies (EXROF), AMC Entertainment (AMC), Alpha Lithium (APHLF) and Avino Silver & Gold Mines (ASM).

Company Calendar

Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VLON
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$-7,020,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$100,000.00
Book Value
$0.18 per share

Miscellaneous

Free Float
8,453,000
Market Cap
$8.61 million
Optionable
Not Optionable
Beta
-1.14
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:VLON) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners